Trial Profile
A Phase II Study of Iodine-131-Labeled Tositumomab in Combination With Cyclophosphamide, Doxorubicin, Vincristine, Prednisone and Rituximab Therapy for Patients With Advanced Stage Follicular Non-Hodgkin's Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Tositumomab; Vincristine
- Indications B-cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 31 May 2020 Results establishing if BMB add value in assessing response or identify distinct progression free (PFS) or overall survival (OS) outcomes in a large, multicenter, multi-trial cohort presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 15 Aug 2019 Status changed from active, no longer recruiting to completed.
- 21 Mar 2019 Planned End Date changed from 1 Feb 2019 to 1 Jun 2019.